Connect with us

Hi, what are you looking for?

The Smart Citizen Report


AstraZeneca COVID-19 sales jump as drugmaker navigates vaccine challenges

Economy6 minutes ago (Jul 29, 2021 07:36AM ET)

(C) Reuters. FILE PHOTO: A health worker shows a vial of the AstraZeneca COVID-19 vaccine against the coronavirus disease (COVID-19) as Thailand start a mass inoculation at a gymnasium inside the Thammasat University in Pathum Thani, Thailand June 7, 2021. REUTERS/Ath

By Pushkala Aripaka and Alistair Smout

(Reuters) -Second-quarter sales of AstraZeneca (NASDAQ:AZN)’s COVID-19 vaccine more than tripled to $894 million from the first quarter, but the drugmaker on Thursday again delayed its U.S. application for approval as it gathers more data for submissions.

The vaccine has been touted as a major weapon against the pandemic because it is cheaper and easier to use than some rivals. AstraZeneca and its Indian manufacturing partner say they have supplied a billion doses to 170 countries so far.

The company began work on the vaccine last year after teaming up with the University of Oxford, despite having no prior vaccine experience.

But the shot has also faced setbacks, including disputes over data, production problems, and links to rare side-effects that have led some countries to stop or restrict its use. The United States has been particularly critical of the vaccine.

AstraZeneca said on Thursday it now expected to seek U.S. approval for the vaccine in the second half of this year, and it still hopeful the shot will have a role to play there. Previously, it had planned an application during the first half.

A senior executive separately told Reuters that the company was exploring options for the future of its COVID-19 vaccine business, with more clarity on the matter expected by the end of the year.

Elsewhere, AstraZeneca is hoping for a boost from the recent purchase of rare medicines business Alexion (NASDAQ:ALXN).

Including Alexion, it now expects total revenue to increase by a low-twenties percentage this year, and core earnings of $5.05 to $5.40 per share. The forecasts do not include sales from the vaccine.

AstraZeneca shares fell 1.4% in early trade but had recovered the losses and edged higher by 1109 GMT.


The Anglo-Swedish drugmaker is also hoping to settle legal proceedings with the European Commission over vaccine delivery commitments.

Despite setbacks, the company said the vaccine, Vaxzevria, brought in $1.17 billion in sales in the first six months of year, putting it among its best selling products, behind first-placed lung cancer drug Tagrisso on $2.54 billion.

Vaccine sales were based on deliveries of about 319 million doses, it said, giving an average price of about $3.7 per dose. Deliveries from its partner, India-based Serum Institute, were not included.

AstraZeneca has said it will not make a profit from the shot during the pandemic but hopes to eventually generate earnings to make the business sustainable. Costs related to the vaccine shaved a cent off second-quarter earnings per share. That was down from 3 cents in the previous three months.

The company said it was also looking into how long the vaccine’s protection lasts and if a booster dose would be needed to keep up immunity.

“People received their second dose, at the earliest in March/April this year, so we need more time to know whether the protection is lasting or needs boosting,” CEO Pascal Soriot said at a media briefing.

While AstraZeneca did not forecast vaccine sales for the year, rivals Pfizer (NYSE:PFE), Moderna (NASDAQ:MRNA) and Johnson & Johnson (NYSE:JNJ) have guided to $33.5 billion, $19.2 billion and $2.5 billion for their COVID-19 shots, respectively.

Total revenue of $8.22 billion for the three months to June beat analysts’ consensus forecast of $7.58 billion. But core earnings of 90 cents per share fell short of an estimated 92 cents.

AstraZeneca COVID-19 sales jump as drugmaker navigates vaccine challenges

Join Our Time-Limited Free Subscription! Get Latest Trading Ideas, Business Info and Market Stocks.

Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

You May Also Like

Editor's Pick

 Going Full Liberal In response to the arrest of a man who walked into a cafe holding a baseball bat and screaming through a megaphone, a...


Cryptocurrency1 hour ago (Mar 15, 2021 05:00AM ET) XRP Price Prediction if It Wins Lawsuit 2020 was a striking year for cryptocurrencies as it...

Editor's Pick

Going Full Liberal More trouble for creepy Joe. An extensive new survey by Morning Consult of nearly 28,000 registered voters presents some troubling numbers for the...


World50 minutes ago (Jul 23, 2021 08:52AM ET) (C) Reuters. FILE PHOTO: A medical worker prepares a syringe at a coronavirus disease (COVID-19) vaccination...

Editor's Pick

Going Full Liberal National Public Radio (NPR) posted a tweet Saturday urging every reader to begin “decolonizing your bookshelf.” According to NPR, “white voices...

Editor's Pick

Going Full Liberal The liberal plan?  Get the body count as high as possible to hurt Trump.  These people are disgusting. Last week, the...

Editor's Pick

Going Full Liberal Liberal brilliance on full display. New York City appears to have experienced a surge in shootings this week after the New...

Editor's Pick

Going Full Liberal The Justice Department released Peter Strzok notes from 1/4/2017 regarding the Flynn-Kislyak calls. Last month it was revealed 2020 Democrat presidential...

Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice.

The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

© Copyright 2021, All Rights Reserved